Recent progress in molecular and immune classification and combined immune target and therapy of hepatocellular carcinoma
10.3760/cma.j.cn113884-20200619-00332
- VernacularTitle:肝癌分子与免疫分型及免疫联合靶向治疗研究进展
- Author:
Tongjing XING
1
Author Information
1. 浙江省台州医院感染科肝病中心，浙江台州 317000
- Keywords:
Liver neoplasms;
Molecular and immune classification;
Targeted therapy
- From:
Chinese Journal of Hepatobiliary Surgery
2021;27(7):549-552
- CountryChina
- Language:Chinese
-
Abstract:
Liver cancer has a high degree of heterogeneity. The molecular characteristics of tumor in different patients, and even in the same liver cancer tissues can be significantly different. Current clinical and pathological classifications cannot accurately evaluate the heterogeneity of liver cancer. With recent developments in genomics, proteomics and metabonomics of liver cancer, molecular classification of liver cancer has made some progress. Intensive research on the immune microenvironment of liver cancer has promoted the recognition of immunological classification of liver cancer. However, none of these classifications can be translated into treatment strategies to guide clinical practice. Immunotherapy combined with antiangiogenic targeted drugs have achieved a great breakthrough in treating patients with advanced liver cancer. It is becoming established as the first-line treatment for patients with advanced, or even intermediate stage of liver cancer. In this review, recent research progress on` molecular and immunophenotyping and immune checkpoint inhibitors combined with antiangiogenesis inbibitors in advanced liver cancer are elaborated.
